Basic jScrollPane demo
Downloads

Test

News

14.3.14

FIRST DATA ON CYONET’S LIVER CELL THERAPY FOR UREA CYCLE DISORDERS PRESENTED AT THE ANNUAL MEETING OF THE SOCIETY FOR INHERITED METABOLIC DISORDERS (SIMD)

Weinheim, Germany and Raleigh-Durham, NC, March 10, 2014 – Interim data on the use of liver cell therapy (LCT) for the treatment of pediatric patients with Urea Cycle Disorders (UCD) were presented today at the Annual Meeting of the Society for Inherited Metabolic Disorders (SIMD) in Pacific Grove, California.

16.1.14

CYTONET SUBMITS EUROPEAN APPROVAL APPLICATION FOR LIVER CELL THERAPY TO TREAT UREA CYCLE DISORDERS IN CHILDREN

Weinheim/Germany, January, 2014 – International biotechnology firm Cytonet announced today that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) seeking approval for its liver cell therapy for the treatment of Urea Cycle Disorders (UCD) in children.

UCD is a life-threatening liver metabolism disorder which can affect newborns and infants, causing toxic levels of ammonia to accumulate in the body. This can lead to massive damage of the brain and nervous system. Cytonet’s liver cell therapy has the potential to stabilize ammonia levels through infusion of healthy liver cells, potentially increasing the length of time children can safely wait until they can undergo a liver transplant.

25.8.13

Liver cell therapy: Urea cycle defects – SELICA-clinical trial program

In December 2013, Cytonet cleared a further vital hurdle – it submitted liver cell therapy for the treatment of congenital urea cycle defects to the European Medicines Agency EMA for regulatory approval. In the August 2013 issue of our newsletter, there is a concise summary of the very rare metabolic disorder of the liver „congenital urea cycle defects”, as well as information on the SELICA-clinical trial program in Europe and North America to study liver cell therapy in newborns and children up to 5 years of age. For more information please look here:  Cytonet Newsletter August 2013

6.8.12

Cure the Cycle Challenge

The Cure the Cycle Challenge is an annual event, comprising a full day bike ride through Napa Valley. Participants in the Challenge raise money and awareness for Urea Cycle Disorders. The event was created by the National Urea Cycle Disorders Foundation (NUCDF) and a link to the event site can be found here http://curethecycle.dojiggy.com/.

29.2.12

Cytonet Recognizes Rare Disease Day with Efforts to Help Ensure – UCD Diagnoses Are Not Missed

Heidelberg/Germany, February 27, 2012 – For parents of babies born with urea cycle disorders (UCD), the joy of giving birth to a perfect baby can quickly turn to devastation as the baby’s health rapidly declines, going from symptoms such as being tired and irritable, to not eating, to experiencing seizures and coma. UCDs are congenital and often life-threatening disorders of ammonia metabolism in the liver that cause neurotoxic ammonia to accumulate in the body, potentially leading to massive damage of the nerves and the brain and death.

14.2.12

Cytonet Trials Aim to Better Assess Severity of Urea Cycle Disorders – Using New Assay for Urea Production

Heidelberg/Germany, February 2012 – International biotechnology firm Cytonet has launched a new clinical trial in Germany to compare the urea cycle activity of pediatric  patients suffering from urea cycle disorders (UCD) to normal healthy children using an innovative assay to measure urea production. Researchers hope to provide a diagnostic tool to predict the severity of the urea cycle defect.

6.12.11

CYTONET SPONORS RIDER ON DONATE LIFE ROSE PARADE FLOAT

Fort Worth/ Texas, November 2011 Giant floral clocks will rise above 28 individuals whose participation as riders aboard Donate Life’s ninth Rose Parade Float will inspire others to save and heal lives through the gifts of organ, eye and tissue donation.  Through their life-changing experiences, the families of organ and tissue donors, living donors and recipients know intimately the preciousness of time. On Jan. 2, 2012 their presence will help bring special meaning to the float’s theme, “One More Day.”

6.12.11

American SELICA III trial to be extended into Canada

Weinheim/ Germany, October 2011 –The Canadian health authority, Health Canada, recently granted Cytonet approval to extend the SELICA III trial, which has been open in the United States since 2010, into Canada.

The clinical trial is designed to evaluate the safety and efficacy of liver cell therapy in infants to children up to age 5 with urea cycle disorders (UCD). Two centers in Canada join the 12 medical centers in the United States taking part in the trial: the Alberta Children’s Hospital in Calgary and the Hospital for Sick Kids in Toronto.

4.7.11

‘Top 100’ recognises the country’s most innovative companies. This year, Cytonet GmbH & Co. KG is among them

Weinheim, Germany, 1st July 2011 – Dedicated employees, creative inquiry and above all the courage to dare to venture into largely ‘undeveloped ground’ of medicine have brought this medium-sized enterprise to the top – to a position on the list of Germany’s 100 top innovators. On Thursday evening, in Rostock Warnemünde, Lothar Späth presented Cytonet, the medical-biotechnological company with the ‘Top 100’ seal of quality.